Alteogen Inc. is a South Korea–based biopharmaceutical company specializing in biologic medicines and drug delivery technologies. The company focuses on improving the administration and performance of large‑molecule therapeutics and is publicly listed on KOSDAQ.
Alteogen’s core platforms include a recombinant human hyaluronidase (ALT‑B4) that enables high‑volume subcutaneous delivery of monoclonal antibodies and other biologics, alongside programs in biosimilars and biobetters spanning oncology and ophthalmology. The company advances its own pipeline and out‑licenses technology to global pharmaceutical partners, supported by R&D, formulation, and process development operations in Daejeon, South Korea.